Consolidation ALK Tyrosine Kinase Inhibitor in Definitively Treated Unresectable Stage III ALK+ NSCLC: Can Real-World Data Inform Clinical Decision in the Absence of a LAURA-Type Designed Trial?
1 Division of Hematology/Oncology, University of California Irvine School of Medicine, Orange/Irvine, California; Chao Family Comprehensive Cancer Center, Orange/Irvine, California.
2 Division of Hematology/Oncology, University of California Irvine School of Medicine, Orange/Irvine, California; Chao Family Comprehensive Cancer Center, Orange/Irvine, California; St. Marianna University School of Medicine, Kawasaki, Japan. Electronic address: [email protected].